Ascendis Pharma expects significant revenue growth with new medicines and strategic roadmap

From GlobeNewswire: 2025-01-12 17:00:00

Ascendis Pharma A/S is set for rapid revenue growth with the launch of two new medicines and planned filings for a third, all utilizing their TransCon technology platform. Key updates include SKYTROFA full-year 2024 revenue expected to be around €202 million, YORVIPATH full-year 2024 revenue estimate of ~€29 million, and plans to submit an NDA for TransCon CNP for achondroplasia in Q1 2025. Financially, Ascendis recorded total full-year 2024 product revenue of ~€226 million and a pro forma cash balance of ~€655 million as of December 31, 2024. The company’s CEO will present these updates at the J.P. Morgan Healthcare Conference on January 13, 2025.



Read more at GlobeNewswire: Ascendis Pharma Provides Business and Strategic Roadmap